Plasma free DNA methylation gene combination for identifying benign and malignant pulmonary nodules, and application of plasma free DNA methylation gene combination

A technology of gene combination and methylation, applied in the direction of recombinant DNA technology, DNA/RNA fragments, biochemical equipment and methods, etc., can solve the problems of difficult and invasive diagnosis of benign and malignant pulmonary nodules, and improve the detection accuracy , reduce the false positive rate, improve the detection of clinical sensitivity and clinical specificity
CN112094912APending Publication Date: 2020-12-18CHINA PHARM UNIV
7 Cites 6 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CHINA PHARM UNIV
Publication Date
2020-12-18

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a plasma free DNA methylation gene combination for identifying benign and malignant pulmonary nodules, and application of the plasma free DNA methylation gene combination. Theplasma free DNA methylation gene combination for identifying benign and malignant pulmonary nodules is selected from at least any two of SOX17, SCT, RASSF1A, SHOX2, HOXA7 and CDO1. The invention discloses application of the plasma free DNA methylation gene combination as a detection target in preparation of a reagent for identifying benign and malignant pulmonary nodules. According to the technical scheme in the invention, a methylation relative quantification method is adopted; the GAPDH is mainly used as an internal reference; a methylation relative quantification reference product is constructed; and then, a relative methylation standard curve is made. The methylation degree of a lung malignant tumour related gene can be obtained through a standard curve; compared with methylation quantitative detection, the gene combination is more sensitive; the detection accuracy is improved; the false positive rate is reduced; and the gene combination has more clinical value for diagnosis of benign and malignant pulmonary nodules.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of biological detection, and relates to a plasma free DNA methylation gene combination for differentiating benign and malignant pulmonary nodules and its application. Background technique

[0002] In 2011, the National Lung Screening Trial (NLST) randomized controlled study showed that compared with chest X-rays, low-dose chest CT screening for high-risk groups can reduce the mortality rate of lung cancer by 20%. %, in view of the above research results, my country recommends that high-risk groups of lung cancer should undergo annual low-dose CT screening for early diagnosis of lung cancer. However, low-dose spiral CT can only identify pulmonary nodules, but its sensitivity to the differential diagnosis of benign and malignant pulmonary nodules is relatively low, that is, the false positive rate is as high as 96.4%, which brings some troubles to patients. According to the "Chinese Expert Consensus on the Diagnosis and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More